“A truthful irrelevancy” – Bass responds to Celgene accusations, files three IPRs
The Coalition for Affordable Drugs has filed its opposition to Celgene’s motion for sanctions in an IPR, arguing that profit is the motivation behind almost all PTAB petitions. It has also filed three more IPRs, bringing its total to 19
The Coalition for Affordable Drugs – the entity that hedge fund manager Kyle Bass and nXn owner Erich Spangenberg are using to challenge pharmaceutical patents at the Patent Trial and Appeal Board (PTAB) – has filed its opposition to Celgene’s...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.